Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. by Braunstein, K M et al.
Characterization of the Defect in Activation of Factor
IXChapel Hill by Human Factor XIa
KENNETH M. BRAUNSTEIN, CLAUDIA M. NOYES, MICHAEL J. GRIFFITH,
ROGER L. LUNDBLAD, and HAROLD R. ROBERTS, Departmnents of Medicine,
Pathology, and Biochemistry, Centerfor Thrombosis and Hemostasis, University
of North Carolina School of Medicine, Dental Research Center, University of
North Carolina School of Dentistry, Chapel Hill, North Carolina 27514
A B S T R A C T Factor IXchapel Hill (Factor IXCH), an
abnormal Factor IX molecule isolated from the plasma
of a patient with mild hemophilia B, has previously
been shown to exhibit delayed activation by Factor
XIa and calcium. In this study, we have found that
Factor IXCH is cleaved upon incubation with human
Factor XIa and calcium; however, cleavage of this pro-
tein is not observed by sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis under nonreducing
conditions. Under reducing conditions, the rate of dis-
appearance of the zymogen parallels both the appear-
ance of the heavy chain and the generation of clotting
activity. In addition, a protein band that migrates with
an apparent molecular weight of 45,000 also increases
in parallel with clotting activity. Factor IXCH and
normal Factor IX (Factor IXN), after incubation with
Factor XIa and calcium, were subjected to amino
terminal sequence analysis. Activated Factor IXN is
cleaved at an arginine-alanine (Arg-Ala) bond and an
arginine-valine (Arg-Val) bond as demonstrated by
formation of the three amino terminal sequences cor-
responding to the amino terminal of the light chain,
heavy chain, and activation peptide. However, acti-
vated Factor IXCH has only two amino terminal se-
quences, corresponding to the original amino terminal
sequence and the heavy chain (formed by cleavage at
the Arg-Val bond). It is concluded that the major defect
in Factor IXCH is, the inability of Factor XIa to cleave the
Arg-Ala bond at a significant rate. The rate of forma-
tion ofclotting activity ofFactor IXCH is -60% ofthe rate
of formation of clotting activity of Factor IXN. The
specific clotting activity of activated Factor IXCH is
between 20 and 33% of activated Factor IXN.




Although it has long been known that Factor IX may be
activated by Factor XIa via the intrinsic pathway (1-6),
it has only recently been demonstrated that Factor VIla
in the extrinsic pathway may activate Factor IX (7, 8).
The relative physiological contribution ofboth ofthese
factors to Factor IX activation in vivo is unknown. The
nomenclature of the cleavage products produced
during the activation of normal Factor IX (Factor IXN)1
is shown in Fig. 1. In the presence of Factor XIa and
calcium, an arginine-alanine (Arg-Ala) bond and an
arginine-valine (Arg-Val) bond are cleaved resulting in
the release of an 11,000-mol wt activation peptide and
the formation of a 45,000-mol wt active enzyme,
IXa,B (6). Factor VIIa in the presence of tissue factor
and calcium apparently cleaves Factor IXN at similar
sites (8). However, with both enzymes the order of
bond cleavage has yet to be confirmed (6, 8). An
inactive intermediate, Factor IXa, is formed when only
the Arg-Ala bond is cleaved (6). With Russell's viper
venom and calcium, cleavage occurs at the Arg-Val
bond yielding an active product, IXaa, which has a
molecular weight of 57,000 (6). Human Factors IXaa
and IXaf3 are reported to have similar clotting activity,
whereas bovine Factor IXaa has -50% of the clotting
activity of bovine IXa/3 (6, 9, 10).
In an earlier report from this laboratory some of the
properties of Factor IXChapel Hill (Factor IXCH) iso-
lated from a patient with clinically mild hemophilia B
were described (11). The antigenic level of Factor IX
in the plasma from this individual was equal to the
IAbbreviations used in this paper: CRM, cross-reacting
material; CRM+, CRM positive variants; CRM-, CRM
negative variants; CRMR, CRM reduced variants; Factor
IXCH, Factor IXChapel Hill; Factor IXN, Factor IX normal.
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level of Factor IX antigen in pooled normal plasma.
However, by routine one-stage Factor IX clotting assay,
only 5% Factor IX clotting activity was found. Purified
Factor IXCH was similar to Factor IXN in terms of
molecular weight, amino acid composition, content of
gamma-carboxyglutamic acid residues, carbohydrate
content and composition, and antigenicity. When
monitored by SDS polyacrylamide disc gel electro-
phoresis under nonreduced conditions, Factor IXCH
was not converted at a significant rate to a lower
molecular weight form by incubation with Factor XIa
and Ca++; however, Factor IXN was completely
converted to a 45,000-mol wt species in 30 min. Al-
though a slight decrease in clotting time was detected,
the inability to convert Factor IXCH to the expected
lower molecular weight form (Factor IXa/8) prevented
determination of the specific activity of the activated
molecule. In the absence of a rigorously determined
specific activity for activated Factor IXCH, the relative
effects on clotting activity of a known slow rate of
cleavage by Factor XIa and an unknown activity of
cleaved Factor IXCH could not be distinguished.
In this study we have extended our investigation
to characterize further the defect in Factor IXCH. We
have determined the specific clotting activity of Factor
IXCH cleaved by human Factor XIa in the presence of
calcium, as well as the rate of cleavage of Factor IXCH.
Because the activation of Factor IXCH was not asso-
ciated with a decrease in its apparent molecular
weight, we have also characterized the products formed
by the incubation of Factor IXCH with Factor XIa. The
results of this study suggest that Factor IXCH, in the
presence of human Factor XIa and calcium, has an





(18,000 mol wt )
with decreased specific clotting activity when com-
pared with normal Factor IX.
METHODS
Materials. The patient with Factor IXCH underwent
plasmapheresis twice weekly, after informed consent, until
sufficient plasma was obtained for the studies outlined be-
low. The blood was processed in a manner similar to that
for normal blood as described below. The plasma was
stored at -70°C and thawed at 370C just before use. Normal
human plasma was obtained from Cutter Laboratories (pro-
vided by Dr. Milton Mozen, Berkeley, Calif.) and the Blood
Bank of the North Carolina Memorial Hospital, Chapel
Hill, N. C. Human blood was collected in plastic bags
that contained standard citrate phosphate dextrose as an
anticoagulant and centrifuged at 3,000 g for 30 min at 40C to
render the plasma platelet-poor and free of erythrocytes.
The plasma was then recentrifuged under the same con-
ditions. Some of the normal human plasma was obtained via
an IBM 2997 Blood Cell Separator or a Haemonetics 30-S
Blood Processor (IBM Instruments Inc., White Plains, N. Y.).
The plasma used for purification of normal Factor IX were
either fresh or stored for <2 mo at -70°C.
Barium chloride, polyethylene glycol 20,000, sodium ace-
tate, and sodium azide were purchased from Fisher Scientific
Co., Pittsburgh, Pa. Benzamidine hydrochloride and cyanogen
bromide were purchased from Eastman Laboratory and
Specialty Chemicals, Eastman Kodak Co., Rochester, N. Y.
Tris (hydroxymethyl) amino methane was purchased from
Mallinckrodt, Inc., Science Products Div., St. Louis, Mo.
Heparin (sodium salt), Russell's viper venom, and oval-
bumin were purchased from Sigma Chemical Co., St. Louis,
Mo. Sequencer chemicals were purchased from Beckman
Instruments, Inc., Fullerton, Calif. Sephadex G-200, Sepha-
rose 4B, and DEAE-Sephadex (A-50) were purchased from
Pharmacia Fine Chemicals, Div. of Pharmacia, Inc.,
Piscataway, N. J. Bovine brain cephalin (Thrombofax) was
purchased from Ortho Pharmaceutical, Raritan, N. J. All
materials used in gel electrophoresis were obtained from
Bio-Rad Laboratories, Richmond, Calif. Celite 545 was pur-
C''O Factor IX
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FIGURE 1 Factor IX terminology. Factor IX zymogen is the native form of the protein which
has no clotting activity. Factor IXa is the inactive intermediate formed by cleavage ofthe arginine'46-
alanine'47 bond only. Factor IXaa is the active intermediate formed by cleavage ofthe arginine'8l-
valine182 bond only. Factor IXa,8 is the fully activated enzyme formed by cleavage ofthe argininel'-
alanine'47 and arginine18l-valine'82 bonds. Amino acid numbers are from the sequence of bovine
Factor IX (10).
Defective Activation of Factor IXChape Ili,,ll by Human Factor XIa
Factor IXao
(45,000 mol wt )
I . . -S-S I
1421
chased from Johns-Manville, Denver, Colo. All other
chemicals were of at least reagent grade or better.
Human Factor XIa preparation. 19 g of celite was added
to 950 ml of normal human pooled plasma and stirred con-
tinuously for 10 min at 37°C before centrifugation at 5,600 g
for 10 min. The precipitate was washed three times with 1
liter of distilled water with a 10-min centrifugation at 5,600 g
after each wash. The precipitate was then resuspended in
950 ml of 10% NaCl and stirred constantly for 10 min. After
centrifugation, the supernatant was dialyzed overnight
against three changes of 0.15 M NaOAc, 0.02% NaN3, pH 5.2.
After dialysis the crude Factor XIa was passed over a carboxy-
methylcellulose (12) column (2.5 x 30 cm) equilibrated with
0.15 M NaOAc (pH 5.2). The column was washed with 250 ml
of0. 15 M NaOAc (pH 5.2). Human Factor XIa was eluted with
a linear gradient ofNaOAc 0.15 M (pH 5.2) to 0.33 M sodium
phosphate, 0.5 M NaCl (pH 6.8) (250 ml each). Fractions
containing Factor XIa activity, as measured by shortening of
a modified nonactivated partial thromboplastin time (13), were
pooled and dialyzed overnight against three changes of4 liters
of 0.15 M NaOAc (pH 5.2). The dialyzed material was con-
centrated with PEG 20,000 to a final volume of 3.5 ml and
then placed on a Sephadex G 200 column (3.0 x 60 cm)
equilibrated with NaOAc 0.15 M (pH 5.2). Fractions con-
taining human Factor XIa activity were pooled and placed
on a heparin Sepharose column (2.0 x 5.0 cm) previously
equilibrated with 0.15 M NaOAc (pH 5.2). The column was
washed with 100 ml of 0.15 M NaOAc (pH 5.2), 0.2 M NaCl
(pH 5.2) and the Factor XIa eluted with 0.15 M NaOAc 2.0 M
NaCl (pH 5.2). Factor XIa fractions were again pooled and
dialyzed overnight against 0.15 M NaOAc (pH 5.2). The
dialyzed material was finally concentrated with PEG 20,000
to a volume of 3.5 ml. Portions of 0.5 ml were stored in
polypropylene tubes at -700C. The final material, diluted
1:10 in 0.05 M Tris HC1 (pH 7.4) clotted normal pooled plasma
in plastic tubes in 47 s but had no effect on plasma ob-
tained from a patient with hemophilia B with undetectable
Factor IX clotting activity and antigen levels nor on
fibrinogen after 5 min of incubation at 37°C. The Factor XIa
corrected the clotting defect ofplasma obtained from a patient
severely deficient in Factor XI. The Factor XIa required
calcium for complete activation of Factor IX, indicating
that the Factor XIa contained an insignificant quantity
of kallikrein.
Preparation of Factor IXN and Factor IXCH. Both proteins
were prepared essentially as described (11). A single band
was seen in reduced and nonreduced SDS gels. The final
product contained only Factor IX clotting and antigenic
activity. Other clotting factors were undetectable.
Factor IX activation. The activation of Factor IXN and
Factor IXCH was performed on samples that were desalted
by passage over Sephadex G-25 (medium) columns (1.0 x 10
cm) equilibrated with 0.05 M Tris (pH 7.4). Factor IX was
diluted with 0.05 M Tris (pH 7.4) to a final concentration of
0.56 ,uM solution.2 Human Factor XIa was diluted with 0.05 M
Tris (pH 7.4) to a final concentration of 0.46 ,M. To 1.95 ml
ofFactor IX (final concentration 0.54 ,uM) was added 0.05 ml of
human Factor XIa (final concentration 0.014 ,uM) and 0.010 ml
of 1.0 M CaCl (final concentration 5 mM). Duplicate 0.1 ml
samples were taken at 0, 5, 10, 15, 20, and 30 min for clotting
assay. Factor IXa clotting activity was measured by adding
2 Protein concentrations were determined by absorption
at 280 nM. Concentration of Factor IX was based on the
extinction coefficients (E280 nml%) 11.8 for Factor IXN and 12.5
for Factor IXCH (11). Concentration of Factor XIa was based
on the extinction coefficient 13.4 (6).
0.10 ml of plasma with undetectable Factor IX clotting ac-
tivity and antigen to 0.10 ml of the sample to be tested and
incubating at 37°C in a 12 x 75-mm polystyrene tube for 60 s.
0.2 ml of a buffered Thrombofax solution (5 ml of calcium
imidazole saline,3 4.5 ml of normal saline, and 0.5 ml of
Thrombofax) was then added to the mixture and a stopwatch
was started. The tubes were shaken 20 times and after 30 s at
37°C, the clotting time was determined. Both Factor IXN
and Factor IXCH were tested at the same time in an identical
manner. After determining that Factor IXN was fully activated
after 30-min incubation, a standard curve was made of the
normal product by preparing dilutions of the fully activated
material in 0.05 M Tris (pH 7.4) of 50, 33, 20, 12.5, and 6.25%.
The clotting times were plotted on a log-log graph and a
straight line was obtained as described by DiScipio et al.
(6). From this standard curve the percent activation was
extrapolated for the time points previously measured. After
30 min all of the Factor IXN zymogen had been cleaved to
the activated product as demonstrated by electrophoresis on
7.5% polyacrylamide gels under reducing conditions with
,3-mercaptoethanol as described by Weber and Osborn (14).
The specific activity of Factor IXCH was determined by
running the activation as previously described with three dif-
ferent Factor XIa concentrations yielding enzyme substrate
ratios of 1:10, 1:20, and 1:40. Determination ofthe percentage
of Factor IX activity of Factor IXCH was continued until all
of the Factor IXCH zymogen had been cleaved.
Monitoring Factor IX activation by polyacrylamide gel
electrophoresis. Factor XIa was incubated with 5 mM CaCl2
and Factor IX for 30 min. The final concentrations of Factor
XIa and Factor IX were 0.09 uM and 1.75 ,uM, respectively.
10 ,ug ofthe activated Factor IX was removed from the reaction
mixture at 0, 5, 10, 15, 20, and 30 min and placed in a solution
of 1% SDS, dithiothreitol (7 mg/ml), and 5 mM EDTA at
56°C for 1 h. The samples were electrophoresed by the
method of Wyckoff et al. (15). The gels were stained with
Coomassie Blue and scanned using a Soft Laser Scanning
Densitometer, Biomed Instruments, Inc., Chicago, Ill. The
areas under the peaks were determined and their relative
amounts calculated. Purified Russell's viper venom (16) in an
enzyme/substrate ratio of 1:3 was incubated with Factors IXN
and IXCH in 5 mM CaCl. Samples were taken at starting time,
15, and 30 min for electrophoresis on reduced and non-
reduced polyacrylamide gels by the method of Weber and
Osborn (14).
Sequence analysis. 10 nmol of Factor IXCH and 5 nmol of
Factor IXN were incubated with Factor XIa at an enzyme/
substrate ratio of 1:20 and 5 mM CaCl2 in a total volume of
2 ml. Initial samples and 60-min samples were exposed to
0.5 ml of 50% acetic acid to inactivate the Factor XIa. The
samples were dialylzed against 4 liters of 5% acetic acid and
subjected to amino terminal sequence analysis.
Automated Edman degradations (17) were performed by a
Beckman 890C sequencer (Beckman Instruments, Inc.). The
0.1 M Quadrol program of Brauer et al. (18) was used, with
modification of the cleavage portion to minimize blowing
of heptafluorobutyric acid vapors through the effluent valve.
The phenylthiohydantoin amino acids produced by the
Edman degradation were identified by high performance
liquid chromatography, using a 4.6-mm, i.d. x 250-mm Ultra-
sphere-ODS column with a Beckman model 324 gradient
liquid chromatograph (Beckman Instruments, Inc.) and model
3 Calcium imidazole saline is 560 ml of 0.082 M CaCl2,
480 ml of 0.253 M imidazole buffer pH 7.2, and 400 ml of
normal saline (0.15 M).
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153 absorbance detector operated at 254 nm. Absorbance at
323 nm (for detection of phenylthiohydantoin-dehydro-
threonine) was monitored by an Isco model 1840 variable
wavelength detector (Instrumentation Specialties Company,
Lincoln, Nebr.). A 2.1-mm, i.d. x 7-cm guard column filled
with Co:Pell ODS (Whatman, Inc., Chemical Separation
Div., Clifton, N. J.) was connected ahead of the analytical
column. Gradient elution was performed at 55°C with an
acetate buffer: acetonitrile solvent system.4
RESULTS
Factor IXN and Factor IXCH were incubated at 37°C
for 60 min with Factor XIa in the presence of 5 mM
Ca++. Samples were removed and subjected to SDS
polyacrylamide gel electrophoresis under reducing
and nonreducing conditions. The Coomassie Blue-
stained gels are shown in Fig. 2. Under nonreducing
conditions it was observed that the mol wt of Factor
IXN was reduced from 58,000 for the zymogen to 48,000
for Factor IXaf8; however, the mol wt of Factor IXCH
was unchanged. Under reducing conditions, two major
bands could be observed for Factor IXN. One band
(the heavy chain of IXa,8) appeared to correspond to a mol
wt of -29,000 whereas the other band (the light chain
of IXaI3) had an apparent mol wt of -22,000. Factor
IXCH also appeared as two bands (in addition to the
original zymogen) under reducing conditions (Fig. 2).
One band migrated with a mobility identical to that
of the heavy chain band from Factor IXN. The other
band, however, had an apparent mol wt of 45,000,
which corresponded to a cleavage product composed
of the light chain and activation peptide found on
cleavage of both Factor IXN and Factor IXCH by
Russell's viper venom (not shown).
The relative rates of cleavage of Factor IXN and
Factor IXCH were determined by scanning poly-
acrylamide gels of reduced samples taken at various
times of incubation (Fig. 3A and B). With both Factor
IXN and Factor IXCH the rate ofdecrease in the zymogen
band was nearly identical to the rate of increase in the
heavy chain band (Fig. 3B). However, the rate of
cleavage of Factor IXCH was 60% of the rate of Factor
IXN cleavage under these experimental conditions.
The rate of increase in the intermediate 45,000 mol wt
band for Factor IXCH was also nearly identical to the
rate of decrease in Factor IXCH zymogen (Fig. 3A). A
45,000 mol wt band was also apparent in gels from
Factor IXN but was present in only small amounts and
remained essentially constant during the period of in-
cubation (Fig. 3A). The light chain band from Factor
IXN cleavage did not appear in the first 10 min of
incubation but increased significantly after that time
(Fig. 3B). There was no evidence of light chain
products derived from Factor IXCH by this technique.








FIGURE 2 Factor IXN and Factor IXCH after Factor XIa
cleavage. 7.5% polyacrylamide SDS disc gel electrophoresis
of: (1) nonreduced Factor IXN; (2) nonreduced Factor IXCH;
(3) reduced Factor IXN, and (4) reduced Factor IXCH. All
samples had been incubated with human XIa and 5 mM CaCl2
at 37°C for 60 min, as described in Methods section. Z,
zymogen; Int., intermediate band; HC, heavy chain, LC,
light chain.
In an attempt to confirm the identity of the cleavage
products formed by incubation of Factor IXCH with
Factor XIa, samples were prepared for sequence analy-
sis of the amino terminal regions of the resulting
activation products. (The samples used were those
shown in Fig. 2). Unactivated Factor IXN and Factor
IXCH were identical in amino acid sequence through
the first six positions tyrosine-asparagine-serine-
glycine-lysine-leucine (Tyr-Asn-Ser-Gly-Lys-Leu).
The first sequence cycle of activated Factor IXN in-
dicated three amino terminals; Tyr, Ala, Val as shown
in Table I. The amino acids found in the subsequent
cycles likewise corresponded to the reported se-
quences (6) of the light chain, the activation peptide,
and the heavy chain. In contrast, sequence analysis of
Factor XIa-activated Factor IXCH revealed only two
sequences, corresponding to the original amino
terminal of the zymogen (Tyr) and the amino terminal
of the heavy chain (Val) (Table I). No detectable
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FIGURE 3 Scans of SDS gel electro
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activity determined as described ii
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clotting activity of 29%, with a ran
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From the data obtained in four identical experiments,
the rate of Factor IXCH activation was found to be -60%
3XCH Heavy Chain of the rate of activation of Factor IXN. SDS poly-]XN Heavy ChainIXN Light Chain, acrylamide gel electrophoresis of reduced samples
taken during incubation indicated that maximum ac-
tivity for both Factor IXN and Factor IXCH coincided
with complete disappearance of the zymogen band.
DISCUSSION
/ About 10% of hemophilia B patients have a normal
amount of Factor IX antigen (crossreacting material;
CRM) present in their plasma (19). Such variants have
l0 20 30 been termed CRM+. Some hemophilia B patients have
reduced crossreacting material (CRMR) whereas others
ophoresis. Factor IXN have no detectable antigen (CRM-). Only a few of the
with human XIa and CRM+ variants have been investigated. Hemophilia
10, 15, 20, and 30 min BM patients are CRM+ and are severely affected
reaction stopped with .
as were reduced with bleeders. Their defect is characterized by a prolonged
er electrophoresis on plasma ox brain prothrombin time (20). Osterud et al.
ins were stained with were unable to detect a defect in either the activation
ned. The areas under rate or the cleavage products of radiolabeled Factor
eir relative amounts IXBM when incubated with Factor XIa and calcium or
Factor VIla, tissue factor, and calcium (21). However,
Bertina (22) claims to have a Hemophilia BM patient
quence was present. whose Factor IX is not cleaved at the Arg-Val bond by
ds are summarized either Russell's viper venom or Factor XIa. Hemophilia
iat the amino termi- BLeyden has a reduced Factor IX clotting and antigen
for Factor IXCH was level that increases with age (23). In addition, Bertina
hich did not exceed and Veltkamp (24) have identified CRM+ variants that
sequent cycles and have altered heparin and calcium binding. Factor IXCH
was the first IX variant described with a defect in its
bove indicate that activation rate. Osterud et al. (25) have subsequently
tor XIa at the Arg- added three other patients with defective activation
z effect of cleavage rates, but have not described the nature of the defect
clotting assays. To further. In the present study we have identified the
taken after maximal abnormality in the activation of Factor IXCH by human
ren and the clotting Factor XIa, although we have not yet determined the
n Methods. In com- putative amino acid substitution.
KCH had an average The rate of formation of cleavage products deter-
ige of 20 to 33% on mined by gel scanning revealed unexpected results.
Ltion of clotting ac- Whereas the clotting activity of Factor IXN coincides
samples taken at with the formation of the heavy chain (Arg-Val
Factor XIa to Factor cleavage), there is an apparent lag in the appearance
tre shown in Fig. 4. of the light chain (Arg-Ala cleavage) relative to the
TABLE I
Amino Terminal Sequences Derived from Factor XIa-activated IXN and IXcH
1 2 3 4 5 6
Light chain IXN Tyr Asn Ser Gly Lys Leu
Light chain-activation peptide IXCH Tyr Asn Ser Gly Lys Leu
Heavy chain IXN Val Val Gly Gly Glu Asp
Heavy chain IXCH Val Val Gly Gly Glu Asp
Activation peptide IXN Ala Glu Thr Val Phe Pro
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TABLE II
Amino Terminal Amino Acids from Factor XIa-Activated






* The amount of Factor IXCH used in these experiments was
approximately twice that of Factor IXN-
appearance of the heavy chain. Furthermore, a protein
band appears in trace amounts in the reduced gels of
partially activated Factor IXN and corresponds to the
peptide band composed of light chain and activation
peptide seen in the reduced gels of activated Factor
IXCH (or Russell's viper venom activated IXN). Thus,
the activation of Factor IXCH by XIa gives rise to a
product similar to IXaa. Because Factor IXCH can be
activated by human Factor XIa without the cleavage
of the Arg-Ala bond, it is clear that the cleavage of this
bond is not an absolute prerequisite for the cleavage
of the Arg-Val bond by human Factor XIa. These data,
particularly the lag in the appearance of the Factor IXN
light chain, suggest that the cleavage of the Arg-Val
bond may precede cleavage of the Arg-Ala bond in
human Factor IX. This is different from the activation
of bovine Factor IX where it appears that the cleavage
of the Arg'46-Ala147 bond precedes the cleavage of
the Arg181-Val182 bond by bovine Factor XIa (9, 10).
It is interesting to note that the apparent molecular
weight of the light chain and the light chain-activation
peptide component are somewhat heavier as judged by
SDS polyacrylamide disc gel electrophoresis than ex-
pected. Precise explanation for this observation can-
not be given; however, it is well-known that glyco-
proteins may migrate with higher apparent molecular
weights than expected in SDS-polyacrylamide gel
electrophoresis (26). From the reported carbohydrate
composition of human Factor IX (6), it is known that
all three peptides (heavy chain, light chain, and
activation peptide) contain significant carbohydrate
and, thus, could migrate in an unexpected manner
on SDS disc gel electrophoresis.
By comparison with Factor IXN, Factor IXCH is distin-
guishable by a slower rate of activation (-60%) and a
lower final specific activity (-30%). These observations
can be contrasted with the 5% Factor IX activity deter-
mined for Factor IXCH by a one-stage clotting assay.
The relatively low specific activity ofthe fully activated
Factor IXCH may be related to the fact that Factor IXCH
is cleaved by Factor XIa to a Factor IXaa form rather
than to the Factor IXaf3 form. Because normal human
OR
100







FIGURE 4 Generation of clotting activity vs. time. Factor IXN
and Factor IXCH were each incubated with human XIa and
5 mM CaCl. At times of 0, 5, 10, 15, 20, and 30 min, portions
ofthe reaction mixture were removed and clotting times were
determined in duplicate as described in Methods. At 30 min
all ofthe Factor IXN zymogen had been cleaved and a standard
curve was made from dilutions of 50, 33, 20, 12.5, and 6.25%.
From this standard curve the percent activation was deter-
mined for the time points previously measured.
Factor IXaa is reportedly as active as Factor IXaf3 (6),
it is not clear that the lack of cleavage of the Arg-Ala
bond in Factor IXCH would necessarily decrease its
specific clotting activity. It is not possible at the present
time to speculate further concerning the region of
Factor IXCH where an amino acid substitution would
lead to the observed effect.
Factor IXCH has given us new insights into the
mechanism of Factor IX activation. The formation of
Factor IXcHaa by human Factor XIa indicates that
cleavage ofthe Arg-Ala bond is not an absolute require-
ment for human Factor XIa cleavage of the Arg-Val
bond. This is further supported by the appearance in
Factor IXN of an intermediate peptide, which corre-
sponds to the light chain-activation peptide band of
Factor IXCH. Interestingly, the patient has only a mild
bleeding tendency. Whether this represents significant
generation of Factor IX activity via the intrinsic
Factor XIa system, or whether this is due to the ability
of Factor VIIa to overcome the molecular defect in
Factor IXCH, at present, remains speculative. However,
this variant of hemophilia B may be particularly im-
portant in establishing the significance of the inter-
actions of Factor IX with Factor XIa and Factor VIIa.
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